|
Video: What is a Stock Split?
|
|
VYNE Therapeutics is a biopharmaceutical company that develops therapies for the treatment of immuno-inflammatory conditions. Co.'s primary program is VYN201, an administered pan-bromodomain and extra-terminal (BET) inhibitor to address diseases involving multiple inflammatory cell signaling pathways while providing low systemic exposure. Co.'s second program is VYN202, a BD2-selective oral small molecule BET inhibitor. VYN202 is in preclinical development for the treatment of immuno-inflammatory indications. FMX114 is Co.'s proprietary investigational combination gel formulation of tofacitinib and fingolimod that addresses both the source and cause of inflammation in atopic dermatitis. According to our VYNE split history records, VYNE Therapeutics has had 2 splits. | |
|
VYNE Therapeutics (VYNE) has 2 splits in our VYNE split history database. The first split for VYNE took place on February 16, 2021. This was a 1 for 4 reverse split, meaning for each 4 shares of VYNE owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 250 share position following the split. VYNE's second split took place on February 13, 2023. This was a 1 for 18 reverse split, meaning for each 18 shares of VYNE owned pre-split, the shareholder now owned 1 share. For example, a 250 share position pre-split, became a 13.8888888888889 share position following the split.
When a company such as VYNE Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the VYNE split history from start to finish, an original position size of 1000 shares would have turned into 13.8888888888889 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into VYNE Therapeutics shares, starting with a $10,000 purchase of VYNE, presented on a split-history-adjusted basis factoring in the complete VYNE split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
01/26/2018 |
|
End date: |
04/24/2024 |
|
Start price/share: |
$2,052.72 |
|
End price/share: |
$2.57 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.87% |
|
Average Annual Total Return: |
-65.71% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$12.52 |
|
Years: |
6.24 |
|
|
|
Date |
Ratio |
02/16/2021 | 1 for 4 | 02/13/2023 | 1 for 18 |
|
|